RESUMO
Recently, China has been facing the dual challenges of air pollution control and carbon emission reduction. Pollution and carbon reduction have become a breakthrough point for green socio-economic transformation. Air pollutant and CO2 emission inventories provide a tool for monitoring pollution and carbon reduction; however, there have been some problems in previous studies, including incomplete species coverage, different source classifications, and narrow time scales. Based on the unified emission source classification system and estimation method, an emission inventory was developed for Hebei Province from 2013 to 2020, and the emission trends, structure change, driving force, synergistic benefits, and spatial distribution were analyzed. Hebei Province achieved a balance during the study period in socio-economic development and anthropogenic emission control. SO2 emissions decreased rapidly during the "Ten Atmospheric Measures" period. VOCs and NH3 emissions reduction were more significant during the "Blue Sky Defense War" period. The decrease rates of NOx and PM2.5 emissions were relatively stable, and CO2 emissions increased slightly. The coal-fired treatment effectively reduced the air pollutant and CO2 emissions and strengthening the emission standards for key industries reduced SO2, NOx, and PM2.5 emissions; however, the VOCs emission control requires improvement. Power and residential sources achieved co-reduction of air pollutants and CO2 and reducing residential coal optimized the energy structure, thereby leading to greater synergistic benefits in the residential source. The key pollution and carbon reduction areas in Hebei Province were Shijiazhuang, Tangshan, Handan, Baoding, and Langfang. The methods and conclusions in this study can provide technical and decision-making references for regional pollution and carbon reduction efforts.
RESUMO
BACKGROUND: The emergence of SARS-CoV-2 Omicron subvariants has raised questions regarding resistance to immunity by natural infection or immunization. We examined the sensitivity of Delta and Omicron subvariants (BA.1, BA.1.1, BA.2, BA.2.12.1, BA.4/5, and BA.3) to neutralizing antibodies from BBIBP-CorV-vaccinated and BBIBP-CorV- or ZF2001-boosted individuals, as well as individuals with Delta and BA.1 breakthrough infections, and determined their fusogenicity and infectivity. METHODS: In this cross-sectional study, serum samples from two doses of BBIBP-CorV-vaccinated individuals 1 (n = 36), 3 (n = 36), and 7 (n = 37) months after the second dose; BBIBP-CorV- (n = 25) or ZF2001-boosted (n = 30) individuals; and fully vaccinated individuals with Delta (n = 30) or BA.1 (n = 26) infection were collected. The serum-neutralizing reactivity and potency of bebtelovimab were assessed against D614G, Delta, and Omicron subvariants (BA.1, BA.1.1, BA.2, BA.2.12.1, BA.4/5, and BA.3) through a pseudovirus neutralization assay. The fusogenicity and infectivity of D614G, Delta, and Omicron subvariants were determined by cell-cell fusion assay and pseudovirus infection assay, respectively. RESULTS: Omicron subvariants markedly escaped vaccine-elicited neutralizing antibodies after two doses of BBIBP-CorV with comparable efficiency. A third dose vaccination of BBIBP-CorV or ZF2001 increased neutralizing antibody titers and breadth against Delta and three Omicron subvariants. Delta and BA.1 breakthrough infections induced comparable neutralizing antibody titers against D614G and Delta variants, whereas BA.1 breakthrough infections elicited a stronger and broader antibody response against three Omicron subvariants than Delta breakthrough infections. BA.2.12.1 and BA.4/5 are more resistant to immunity induced by breakthrough infections. Bebtelovimab had no significant loss of potency against the Delta and Omicron subvariants. Cell culture experiments showed Omicron subvariants to be less fusogenic and have higher infectivity than D614G and Delta with comparable efficiency. CONCLUSIONS: These findings have important public health implications and highlight the importance of repeated exposure to SARS-CoV-2 antigens to broaden the neutralizing antibody response against Omicron subvariants.
